Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.

Cancer medicine - 1 Apr 2018

Hui Wen, Liu Shenghua, Zheng Jie, Fang Zujun, Ding Qiang, Feng Chenchen

Abstract excerpt

Adrenocortical carcinoma (ACC) is a rare malignancy, and CTNNB1 is frequently mutated in ACC. Our study aims to screen for effective agents with antineoplastic activity against ACC with CTNNB1 mutation. In-silico screening of the Genomics of Drug Sensitivity in Cancer (GDSC) database was conducted. Drug sensitivity in cells with CTNNB1 mutation was analyzed and further in vitro and in vivo studies were performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hormones
Share to Adrenocortical Carcinoma
Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle

Share to Epithelial-Mesenchymal Transition

Share to Imidazoles

Share to Piperazines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29532999
DOI: 10.1002/cam4.1431
PMCID: PMC5911589

Genes

CTNNB1
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.PMID 29532999Read ↗

Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging OptionsSemantic proximity Read ↗

Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.Semantic proximity Read ↗

Adrenocortical carcinoma: a literature reviewSemantic proximity Read ↗

Adrenocortical cancer.Semantic proximity Read ↗

Molecular genomic profiling of adrenocortical cancers in clinical practice.Semantic proximity Read ↗

Adrenocortical carcinoma.Semantic proximity Read ↗

Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.Semantic proximity Read ↗

Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications.Semantic proximity Read ↗

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.Semantic proximity Read ↗

Updating ACC preclinical models: characterization of two new patient-derived cell linesSemantic proximity Read ↗

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaSemantic proximity Read ↗

Molecular Cluster Mining of Adrenocortical Carcinoma via Multi-Omics Data Analysis Aids Precise Clinical TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.